Al­bert Bourla picks a new deal­mak­er to lead the hunt for more drugs to swell Pfiz­er’s pipeline

A new deal­mak­er is join­ing the ex­ec­u­tive crew at Pfiz­er.

The phar­ma gi­ant says that McK­in­sey vet Aamir Ma­lik is jump­ing on board as a new ex­ec­u­tive vice pres­i­dent and “chief busi­ness in­no­va­tion of­fi­cer.” He’s tak­ing the place of John Young, who had ear­li­er an­nounced plans to re­tire from the phar­ma gi­ant af­ter a 34-year run.

Ma­lik has a tough act to fol­low. In his send­off, CEO Al­bert Bourla cred­it­ed Young with es­tab­lish­ing col­lab­o­ra­tions for the phar­ma gi­ant that led to its in­cred­i­bly prof­itable tie-up with BioN­Tech. That al­liance has de­liv­ered a megablock­buster Covid-19 vac­cine that promis­es to earn tens of bil­lions of dol­lars.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN